DOACs — patient guide (apixaban, rivaroxaban, dabigatran, edoxaban)

This page covers all four direct oral anticoagulants — apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Lixiana). If your medicine is one of these, this is your page. Unlike most drug families on this site, there is no shared -pril or -statin suffix — the four DOACs are grouped by mechanism rather than by name.

---

Start here — what these tablets actually do

You are on a DOAC because something in your circulation has crossed a line that warrants thinning the blood. The line is usually one of three: atrial fibrillation with a stroke-risk score that justifies stroke prevention; a venous clot (a deep vein thrombosis or a pulmonary embolism) that needs treatment and a period of recurrence prevention; or a clot-protection window after hip or knee replacement surgery. There is also a smaller cardiology-led role for a low dose of rivaroxaban plus low-dose aspirin in stable coronary or peripheral artery disease — that one is initiated by a cardiologist, not in general practice.

The trade-off is the same in every case. Without the medicine, your risk of the clot-driven event (stroke or recurrent clot) is higher than your background risk. With the medicine, that risk drops substantially — but the price is a measurable rise in bleeding risk. The whole job of the management plan is to keep the bleeding risk in a range where the stroke or clot protection is still net-favourable, and to spot the moments when the balance shifts.

This page walks you through the medicine itself, the four members of the family, the moments that change the risk picture (sick days, surgery, new medicines, supplements, falls), and the bleeding signals that warrant an ED visit. Hold both sides of this in your head at the same time — the medicine prevents the thing it was prescribed for, and bleeding risk is the real cost, and both of those statements are true.

---

Find your medicine

Generic name	Common brand names	Strengths	How often
Apixaban	Eliquis, generics	2.5 / 5 mg	Twice daily
Rivaroxaban	Xarelto, generics	2.5 / 10 / 15 / 20 mg	Once daily (twice daily for the 2.5 mg COMPASS regimen and the first 3 weeks of acute VTE at 15 mg)
Dabigatran	Pradaxa	75 / 110 / 150 mg	Twice daily
Edoxaban	Lixiana	30 / 60 mg	Once daily

Dabigatran capsule — swallow whole. Pradaxa capsules must never be opened, crushed, or split, and the contents must never be sprinkled onto food or into drinks. Doing any of those things markedly increases how much active drug is absorbed and pushes bleeding risk up sharply. If swallowing the whole capsule is a problem, message your GP — there are workable alternatives, but the workaround is never to break the capsule.

Rivaroxaban 15 mg and 20 mg — take with food. The 15 mg and 20 mg doses need food in the stomach to be absorbed properly. The 2.5 mg (COMPASS) and 10 mg (post-orthopaedic prophylaxis) doses can be taken with or without food. A regular meal at the same time each day makes this easy.

Closely related — warfarin. Warfarin is the older vitamin-K-antagonist anticoagulant. It is still the right tool for several situations where DOACs are not validated or have been shown to cause harm: mechanical heart valves (per the RE-ALIGN trial), moderate-to-severe mitral stenosis, and triple-positive antiphospholipid syndrome (per the TRAPS trial). It requires regular INR blood tests, has more food and drug interactions, but has decades of safety data in those specific populations.

Closely related — low-molecular-weight heparin (enoxaparin / Clexane, dalteparin / Fragmin). Injectable. The AU standard during pregnancy and breastfeeding, the standard early treatment for many cancer-associated clots, and a common short-term tool around hospital admissions.

---

What these tablets are for

DOACs are prescribed for more than one reason. Your reason is one — or sometimes more than one — of these.

• Stroke prevention in atrial fibrillation. The most common reason. AF causes blood to pool in part of the left atrium and form a clot, which can travel to the brain. A DOAC reduces that stroke risk substantially. The threshold for treatment uses a risk-score system (CHA2DS2-VA) that weighs age, sex, heart failure, hypertension, diabetes, prior stroke, and vascular disease. If you are on a DOAC for AF, the goal is stroke prevention — not rhythm control or symptom control. Those are separate conversations.
• Treatment of a venous clot (DVT or PE). Once a clot has happened, the DOAC stops the existing clot growing and the body breaks it down over weeks to months. Treatment is usually 3 to 6 months for a provoked clot (one with an obvious trigger like surgery, an immobilising injury, or a long flight in a high-risk person) and longer — sometimes indefinitely — for an unprovoked clot or one with ongoing risk factors. The decision about duration is reviewed with your GP and sometimes a haematologist.
• Prevention of recurrent venous clots. After the initial treatment phase, a lower DOAC dose is sometimes continued for ongoing prevention if your recurrence risk is high.
• Clot protection after hip or knee replacement. A defined short course — typically 10–35 days post-operatively — to prevent clots during the high-risk immobilisation window.
• Secondary prevention in stable coronary or peripheral artery disease (rivaroxaban 2.5 mg twice daily plus low-dose aspirin — the COMPASS regimen). A specialised cardiology-initiated indication. This is not a general substitute for usual antiplatelet care, and your GP will not typically change the antiplatelet component without cardiology input.

The mechanism is the same across these reasons. The duration, dose, and review schedule differ. Your GP will tell you which group you’re in — that information shapes what is at stake if a dose is missed, when the medicine might be reviewed for stopping, and how the conversation about lifestyle changes goes.

---

The basics

1. Take it on time. Once-daily DOACs (rivaroxaban, edoxaban) at the same time each day. Twice-daily DOACs (apixaban, dabigatran) roughly 12 hours apart. Consistency matters more than the exact clock time — pick what fits your life and hold it.
2. Never stop on your own. Unscheduled hold of a DOAC is a real stroke and recurrent-clot risk. Sick-day pauses and surgery holds are both planned conversations, not unilateral decisions.
3. Go to ED for sudden severe headache, weakness or numbness on one side, sudden loss of speech or vision, vomited blood, large fresh blood per rectum, or a head injury with loss of consciousness. The reversal protocol exists; the ED knows it.

Everything else — sick days, surgery, the supplement list, the integrative angle — is below.

---

Sick day rules — when to seek advice early

If any of these happen, contact your GP early rather than waiting it out:

• Vomiting that lasts more than a few hours
• Severe diarrhoea
• Fever where you can’t keep fluids or tablets down
• Heat illness with poor fluid intake
• A fall, especially with a head strike
• New significant dizziness, light-headedness on standing, or unexplained fatigue

These matter on a DOAC for a clear reason. Kidney function can drop. Drug levels can rise. Bleeding risk can spike. All in the same 24 hours.

The action is rarely to stop the DOAC on your own. The action is a same-day call. Sometimes an early kidney blood test. Sometimes a brief planned hold under guidance.

---

Before surgery, a colonoscopy, or any procedure

Any planned procedure — including dental work that involves significant bleeding, colonoscopy with potential biopsy or polypectomy, joint injections, cataract surgery, skin excisions — needs the proceduralist to set the hold window. Typical AU practice, per eTG and THANZ peri-operative guidance:

• Low bleeding-risk procedure, normal kidney function: hold for at least 24 hours before.
• High bleeding-risk procedure, normal kidney function: hold for at least 48 hours before.
• Reduced kidney function (creatinine clearance below 50 mL/min, particularly for dabigatran): extend the hold window — the proceduralist sets the exact timing.
• Resumption is timed to haemostasis: usually 24 hours after a low bleeding-risk procedure, 48–72 hours after a high bleeding-risk procedure.
• Bridging with low-molecular-weight heparin is generally not needed — the predictable on-and-off pharmacokinetics of a DOAC make routine bridging a warfarin-era practice that no longer applies.

Two failure modes to dodge. First — holding the DOAC without specific advice from the proceduralist or GP. Unscheduled stroke or recurrent-clot risk is not trivial, and the procedure may not even need the hold. Second — going into the procedure on a full dose without disclosure. The procedure team needed to know.

---

Tap any section below to expand the detail.

How do they work?

Blood clotting is a cascade — a sequence of proteins that activate each other in order, ending in fibrin strands and a stable clot. DOACs block one specific step in that cascade.

• Dabigatran blocks thrombin (factor IIa) directly — the enzyme that converts fibrinogen to fibrin.
• Apixaban, rivaroxaban, and edoxaban block factor Xa — the enzyme one step upstream of thrombin.

Blocking either step slows clot formation enough to prevent the clinical event (stroke or recurrent venous clot) without abolishing clotting altogether. The body still seals everyday small injuries; it just takes longer and produces more visible bruising.

Compared with warfarin, DOACs have a much shorter half-life (most are out of meaningful clinical effect within 24–48 hours after stopping, longer with reduced kidney function), do not require regular INR monitoring, and have fewer dietary interactions. The trade-off is shorter forgiveness for missed doses and a class-wide reliance on kidney function for clearance.

Bleeding signals — what to do, and when

Call 000 or go straight to ED for any of these:

• Sudden severe headache, especially with weakness, numbness, slurred speech, vision changes, or confusion (possible intracranial haemorrhage)
• Head injury with loss of consciousness or persistent symptoms after the strike
• Vomiting blood or material that looks like coffee grounds
• Large amount of fresh blood from the back passage, or black tarry stools
• Coughing up blood (more than streaks)
• Severe abdominal or back pain that is new and unexplained
• Heavy unexpected vaginal bleeding
• Any major trauma with significant external bleeding

Reversal agents exist. Idarucizumab (Praxbind) is the specific reversal agent for dabigatran and is stocked in AU hospital pharmacies. Andexanet alfa (Ondexxa) is the specific reversal agent for the factor Xa inhibitors (apixaban, rivaroxaban) — AU 2026 access has been uneven, so where andexanet alfa is unavailable, the AU standard-of-care reversal is prothrombin complex concentrate (Beriplex / Prothrombinex-VF) per THANZ guidance. The ED knows the protocol. Tell them which DOAC you take, when your last dose was, and your most recent kidney function if you know it.

Same-day call to your GP for persistent minor bleeding that won’t settle:

• Nosebleeds lasting more than 10–15 minutes despite firm pressure
• Bleeding gums that won’t settle with pressure and a soft toothbrush
• A new bruising pattern you don’t recognise — large bruises, bruises in unusual locations, or bruises appearing without an obvious knock
• Blood in the urine
• Heavier-than-usual menstrual bleeding
• New persistent fatigue, breathlessness, or pallor (occult bleeding can drop iron and haemoglobin slowly without a dramatic event)

Drug and supplement interactions

DOACs have fewer interactions than warfarin, but the ones they do have matter.

Avoid or use with specific advice:

• Strong CYP3A4 and P-glycoprotein inhibitors — azole antifungals (ketoconazole, itraconazole, posaconazole, voriconazole), the macrolide antibiotic clarithromycin (and to a lesser degree erythromycin), HIV protease inhibitors and ritonavir-boosted regimens, ciclosporin. These increase DOAC exposure and bleeding risk. Some combinations are flat contraindicated; some require dose reduction; some require holding the DOAC for the duration of a short antibiotic or antifungal course. Always cross-check before combining.
• Strong CYP3A4 and P-glycoprotein inducers — rifampicin, phenytoin, carbamazepine, phenobarbital, and St John’s wort. These reduce DOAC exposure and risk treatment failure (recurrent stroke or clot). Combinations are usually avoided; if unavoidable (TB treatment, seizure control), specialist input is required.
• Other anticoagulants — warfarin, heparin, low-molecular-weight heparin, fondaparinux. Combination outside of a planned switching window is not done. Switches between anticoagulants follow specific timing rules per the AMH.

Talk to your GP or pharmacist before combining with:

• NSAIDs — ibuprofen / Nurofen, diclofenac / Voltaren, naproxen, celecoxib. Stack the gastrointestinal and renal bleeding risk on top of the DOAC. Short occasional use is usually manageable; regular daily use is generally avoided. Paracetamol is fine.
• Antiplatelets — aspirin, clopidogrel, ticagrelor, prasugrel. Combination is sometimes intentional (post-acute-coronary-syndrome or post-stent regimens, the COMPASS aspirin-plus-rivaroxaban regimen) and sometimes accidental (over-the-counter aspirin). All combinations magnify bleeding risk and need an explicit indication with a defined duration set by the prescribing cardiologist.
• SSRIs and SNRIs — modest additive gastrointestinal bleeding signal via platelet serotonin depletion. Combination is common and acceptable with awareness; consider stomach protection if other gastrointestinal bleeding risk factors are present.
• Trimethoprim (alone or as co-trimoxazole / Bactrim) — modest additive bleeding signal in some pharmacokinetic data. Short courses are usually fine with awareness.

Supplements worth mentioning at review:

• Fish oil supplements above roughly 3 g per day add an antiplatelet effect on top of the DOAC. Culinary fish intake is fine.
• Concentrated curcumin or turmeric extracts add a bleeding signal. Culinary turmeric in food is fine.
• High-dose vitamin E (above ~400 IU per day) adds a bleeding signal. Multivitamin-level intake is fine.
• Ginkgo biloba has an additive bleeding signal and is generally avoided.
• Pomegranate juice on rivaroxaban — emerging signal of increased drug exposure in small studies. Occasional culinary intake is unlikely to matter; daily concentrated juice or supplements warrant a mention at review.

Food. No specific dietary restrictions for the DOACs themselves. The vitamin-K-rich foods (leafy greens, broccoli) that needed managing on warfarin no longer require managing — eat them freely. Rivaroxaban 15 mg and 20 mg must be taken with food.

Alcohol. Light to moderate intake within NHMRC guidelines is reasonable. Heavy intake stacks bleeding risk (antiplatelet effect, gastric irritation, falls), worsens liver function over time, and disrupts the discipline of taking the medicine on time.

Generic substitution at the pharmacy. Generics are bioequivalent to the branded versions for all four DOACs.

Monitoring — what blood tests and how often

DOACs don’t require INR monitoring (the warfarin blood test). What they do require is periodic kidney function and full blood count monitoring, because both shift over time and either shift can change the bleeding-risk picture.

• Before starting — full blood count, kidney function (creatinine and estimated glomerular filtration rate), liver function tests. These set the baseline and confirm the right drug and dose for your kidneys.
• At least annually — repeat the same tests, with bleeding-risk and stroke-risk reassessment. Earlier and more frequent if you are over 75, frail, on dabigatran with reduced kidney function, on a recent new medicine that interacts, or recovering from a significant illness.
• More urgently — repeat kidney function if you have a significant intercurrent illness (dehydration, hospital admission, new heart failure), if a new nephrotoxic medicine is added (some chemotherapies, certain antibiotics, contrast for imaging), or if you develop new symptoms suggesting reduced kidney function (reduced urine output, marked swelling).
• Bleeding signal monitoring — annual full blood count and iron studies. Slow occult gastrointestinal bleeding can show up as falling haemoglobin and ferritin before it shows up as a dramatic event.

Falls and cognitive decline are bleeding-risk multipliers. If you have had a fall in the last 12 months, particularly with a head strike, ask your GP for an explicit reassessment of the bleeding-risk-versus-stroke-prevention balance. The answer is not always to stop the DOAC — usually it’s to optimise the modifiable bleeding-risk factors (blood pressure, alcohol intake, NSAID use, the medicines and supplements list) and to plan a falls-prevention strategy in parallel.

Stopping or pausing

Never stop on your own. Unscheduled hold of a DOAC has a measurable stroke or recurrent-clot cost in the next 24–72 hours that the prescriber needed to know about.

• If side effects are the problem (dyspepsia on dabigatran, recurrent minor bleeding, an interacting new medicine), the conversation is usually a switch within the class or a careful look at the modifiable bleeding-risk factors — not stopping anticoagulation altogether unless the indication itself has changed.
• Sick-day pauses (severe gastro, dehydration, heat illness) — sometimes the right call under guidance, never a unilateral decision.
• Pre-procedure holds — set by the proceduralist with timing per the section above.
• End-of-treatment decisions — for venous clots, the original 3–6 month treatment phase ends with an explicit review and a deliberate decision either to stop, to continue at a prevention dose, or to continue at full dose indefinitely. That decision belongs in a consult, with the recurrence-risk picture in front of you both.

Pregnancy and breastfeeding

DOACs are contraindicated in pregnancy and breastfeeding. They cross the placenta and are excreted into breast milk to a clinically relevant degree. The AU standard during pregnancy and breastfeeding is low-molecular-weight heparin (enoxaparin / Clexane, dalteparin / Fragmin), which does not cross the placenta.

• Planning a pregnancy on a DOAC: message your GP early. We plan the switch in advance — ideally before conception — rather than at the moment of a positive test.
• Already on a DOAC and just found out you’re pregnant: contact your GP the same day. Don’t panic, but don’t take the next dose until you’ve talked. We’ll arrange the switch and an early obstetric review together.

Cost on the PBS

All four DOACs are on the PBS under Authority Required (Streamlined) listings for their on-label indications — non-valvular atrial fibrillation, treatment and secondary prevention of venous thromboembolism, and prevention of venous thromboembolism after hip or knee replacement. The pharmacist applies the relevant streamlined code at dispense and you pay the standard PBS co-payment.

From 1 January 2026, the PBS co-payment is:

• General patient: up to $25.00 per script
• Concession card holder: up to $7.70 per script

Generics are bioequivalent to the branded versions and are priced at the PBS rate. Your actual charge may be lower if the product price sits below the co-payment, or higher if you choose a brand with a premium. The pharmacist can show you the exact price and the cheapest equivalent for your script.

---

The integrative view

DOACs work, and the trial evidence for stroke prevention in atrial fibrillation and for treatment of venous clots is strong. Lifestyle and nutrient choices don’t replace the medicine for the indications a DOAC was prescribed for. What they do influence is the bleeding-risk side of the equation — and a slow chronic-disease picture in which the indication for anticoagulation might or might not stay the same five years from now.

This section is the longer version of the conversation worth having with your GP.

The bleeding-risk levers you can move

These are the things that genuinely change your bleeding risk on a DOAC. Each one is worth doing — and the effect stacks.

• Blood pressure control. Uncontrolled hypertension is one of the largest modifiable risk factors for intracranial haemorrhage on any anticoagulant. The same lifestyle moves that lower blood pressure on their own — sodium reduction, the DASH-style eating pattern, regular aerobic exercise, weight loss, alcohol moderation, treating sleep apnoea — also reduce your bleeding risk on a DOAC. See the ACE inhibitors and ARBs pages for the longer protocol.
• NSAID minimisation. Regular ibuprofen, diclofenac, or naproxen on a DOAC is the most common avoidable cause of significant gastrointestinal and renal bleeding. Topical NSAID gels and paracetamol are the lower-risk options for the same pain.
• Alcohol moderation. Within NHMRC guidelines and ideally below them. Each drink above 1–2 standard per day adds antiplatelet effect, gastric mucosal irritation, and falls risk on top of the DOAC.
• Falls prevention. Strength training (2–3 sessions per week of resistance exercise), balance work (tai chi, single-leg standing practice, structured falls-prevention physiotherapy), home hazard review (loose rugs, poor lighting, bathroom grab rails), and a vision and hearing check. A fall with a head strike on a DOAC is the most feared scenario; the protective work happens before the fall, not after.
• Adequate hydration. Particularly in heat, illness, or after a hard exercise session. Dehydration drops kidney clearance, raises DOAC exposure, and worsens light-headedness — all at once.

Nutrient considerations that genuinely matter

• Iron, vitamin B12, folate. A DOAC patient with slow occult bleeding (most often gastrointestinal) can become iron-deficient and anaemic over months without a dramatic event. New fatigue, breathlessness, exercise intolerance, or pallor on a DOAC warrants a full blood count and iron studies rather than waiting for the next annual review.
• Vitamin K. Unlike warfarin, DOACs are not affected by dietary vitamin K. If you previously kept your green-leafy intake low to keep INR stable, you can eat leafy greens freely — and the iron, magnesium, calcium, folate, and fibre they bring back into your diet are genuinely useful for the rest of your cardiovascular picture.
• Omega-3s from food. Two oily-fish meals per week (salmon, sardines, mackerel) deliver enough EPA/DHA for cardiovascular benefit without the bleeding-stack of a concentrated supplement.

Supplements to mention at review

Not every supplement adds risk, but a handful reliably do. Mention any of these at your next review:

• Fish oil supplements above roughly 1–2 g per day
• Concentrated curcumin or turmeric extracts (culinary turmeric in food is fine)
• High-dose vitamin E above ~400 IU per day
• Ginkgo biloba
• Daily pomegranate juice or concentrated pomegranate supplements (rivaroxaban specifically)

The framing here isn’t “supplements are bad.” It’s “the bleeding-risk picture is a sum, and the picture changes when something is added.”

Does the indication ever come off?

Sometimes — and the answer depends entirely on why you’re on it.

• Atrial fibrillation — anticoagulation is usually continuing unless the AF itself resolves (after a successful catheter ablation in a low-stroke-risk patient, for example) and the stroke-risk score drops below the treatment threshold. The conversation is with your cardiologist and your GP together, not a unilateral lifestyle decision.
• Provoked venous clot — anticoagulation is usually 3–6 months and then stops or moves to a lower prevention dose, depending on the recurrence-risk picture.
• Unprovoked venous clot, or one with persistent risk factors — often continued indefinitely. Lifestyle change doesn’t typically change that decision, but a haematology review every few years is reasonable.

The honest position is that the medicine is a tool. The reason you’re on it is a separate question. Your GP can tell you which group you’re in — and that frames everything else on this page.

---

Track these between now and your next visit

• Any bleeding — even small (nosebleeds, gum bleeding, unusual bruising). Note frequency and roughly when.
• Any new medicine or supplement bought over the counter or prescribed elsewhere — including short antibiotic or antifungal courses.
• Any illness with vomiting or diarrhoea that affected your dosing.
• Any falls — even ones you got up from without injury. Particularly head strikes.
• Any upcoming procedure — dental work, colonoscopy, joint injection, skin excision, cataract surgery, anything planned.

Bring the list to your review appointment. The picture between visits is the picture that informs the next decision.

---

This is general information, not personal medical advice. Every patient on a DOAC is different. Decisions about which DOAC, what dose, when to hold, and what to combine with are made with the doctor who prescribed it, with your kidney function, body weight, age, falls history, bleeding history, and concurrent medicines in front of them. If anything on this page appears to contradict advice from your treating doctor, follow your doctor — they have context about your situation that this page cannot.

Reading this page does not establish a doctor-patient relationship with Dr Hoebing Lo. If you are not a current patient, please discuss your anticoagulation with your own GP, specialist, or pharmacist.

About the integrative content. The lifestyle, dietary, and supplement information on this page summarises current published research. Effect sizes are approximations from clinical studies — individual responses vary, and real-world results are commonly smaller than trial results because day-to-day life differs from study conditions. Supplements and herbal products are not interchangeable with prescribed anticoagulants and can interact with them. Talk to your doctor and pharmacist before starting any new supplement, herbal product, or significant dietary change.

Currency. This page reflects clinical practice as of the last-reviewed date. The reversal-agent landscape (particularly andexanet alfa availability in AU), PBS listings, and intra-class evidence continue to evolve; specific details may date between reviews. Pricing shown is indicative; confirm with your pharmacist.

No commercial relationships. Dr Hoebing Lo has no financial or commercial relationship with the manufacturer of any anticoagulant, brand, or supplement mentioned on this page.

Emergencies. If you have sudden severe headache, weakness or numbness on one side, slurred speech or vision loss, vomited blood or material that looks like coffee grounds, a large amount of fresh blood from the back passage, a head injury with loss of consciousness, or any major trauma with significant bleeding, call 000 or go to your nearest emergency department. Do not wait, and do not message us first.